Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • G(M2) Ganglioside
  • Gangliosides
  • Melanoma
  • Tumor Cells, Cultured

abstract

  • GM2 ganglioside is a common cell surface constituent of human melanoma and other tumors of neuroectodermal origin, and vaccination with GM2 ganglioside results in high levels of anti-GM2 antibodies in patients with melanoma. Lymphocytes from a GM2-vaccinated patient (VS) were transformed by Epstein-Barr virus and tested for production of antibodies with reactivity for GM2-positive tumor cells. A high percentage of antibody-producing B cells was detected, but antibody reactivity was generally lost during culture expansion. Two cultures, however, remained stable for antibody productivity and one was used to develop a stable hybrid line with mouse myeloma. The monoclonal antibody (designated 3-207) derived from patient VS has dual specificity for GM2 and GD2, despite the fact that only GM2 antibody could be detected in the patient's serum. Monoclonal antibody 3-207 shows high-titered reactivity with a range of melanoma, astrocytoma, neuroblastoma, and leukemia cell lines, cells with prominent cell surface expression of GM2 and GD2. The cell surface reactivity of monoclonal antibody 3-207 was not abolished by treatment of target cells with neuraminidase, as the enzyme converted GD2 to GM2, which was still detected by monoclonal antibody 3-207.

publication date

  • May 1990

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC53894

PubMed ID

  • 2159145

Additional Document Info

start page

  • 3333

end page

  • 7

volume

  • 87

number

  • 9